We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prokinecitine in Acute Myocardial Infarction (Prok-Idm)

This study is currently recruiting participants.
Verified September 2017 by University Hospital, Strasbourg, France
Sponsor:
ClinicalTrials.gov Identifier:
NCT02021487
First Posted: December 27, 2013
Last Update Posted: September 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Strasbourg, France
December 19, 2013
December 27, 2013
September 11, 2017
November 2013
November 2019   (Final data collection date for primary outcome measure)
Infarct size by MRI necrotic myocardial mass [ Time Frame: 7 days ]
Infarct size by MRI necrotic myocardial mass
Same as current
Complete list of historical versions of study NCT02021487 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prokinecitine in Acute Myocardial Infarction
Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction
The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.
Not Provided
Observational
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with acute St elevation myocardial infarction of less than 6 hours
ST Elevatation Myocardial Infarction (STEMI)
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
November 2019
November 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with acute St elevation myocardial infarction of less than 6 hours
  • Age>18 y/o

Exclusion Criteria:

  • Previous myocardial infarction
  • LBB, RBB
  • Renal Insuffiency MDRD<30 mL/min
  • Patient with Pace-Maker or ICD.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Patrick OHLMANN, MD 03 69 55 09 53 ext 0033 patrick.ohlmann@chru-strasbourg.fr
France
 
 
NCT02021487
5515
No
Not Provided
Not Provided
University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
Not Provided
Principal Investigator: Patrick OHLMANN, MD University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
September 2017